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ABSTRACT
With next-generation DNA sequencing tech-
nologies, one can interrogate a specific genomic
region of interest at very high depth of coverage
and identify less prevalent, rare mutations in hetero-
geneous clinical samples. However, the mutation
detection levels are limited by the error rate of
the sequencing technology as well as by the
availability of variant-calling algorithms with high
statistical power and low false positive rates.
We demonstrate that we can robustly detect
mutations at 0.1% fractional representation.
This represents accurate detection of one mutant
per every 1000 wild-type alleles. To achieve
this sensitive level of mutation detection, we inte-
grate a high accuracy indexing strategy and refer-
ence replication for estimating sequencing error
variance. We employ a statistical model to
estimate the error rate at each position of the refer-
ence and to quantify the fraction of variant base in
the sample. Our method is highly specific (99%) and
sensitive (100%) when applied to a known 0.1%
sample fraction admixture of two synthetic DNA
samples to validate our method. As a clinical appli-
cation of this method, we analyzed nine clinical
samples of H1N1 influenza A and detected an
oseltamivir (antiviral therapy) resistance mutation
in the H1N1 neuraminidase gene at a sample
fraction of 0.18%.
INTRODUCTION
With broad applications in research and clinical diagnos-
tics, next-generation DNA sequencing (NGS) has become
an important platform for identifying mutations and
variants from clinical samples. NGS has been frequently
applied to detection of polymorphisms from normal
diploid genomic DNA samples where the allele frequency
is based on Mendelian inheritance. In this case, a hetero-
zygote variant comprises half the depth at its position.
However, many samples represent more complex
mixtures in their genetic composition where a mutation
or variant may be present in only a small proportion of
the relevant sequences. Deep sequencing analysis with
very high levels of coverage on smaller targeted regions
can sensitively detect less prevalent, minor alleles and mu-
tations from these admixed samples. For example,
ultrasensitive detection could identify mutations in indi-
vidual genes that cause resistance to the drugs that target
speciﬁc gene products.
Generally, applications of sensitive rare mutation and
minor allele detection from admixed samples include: mi-
crobial or viral population sequencing, rare cancer-speciﬁc
mutations in primary tumors, environmental diversity
sampling of speciﬁc microbes and pooled sample
sequencing. As noted, many studies are particularly inter-
ested in small sets of genes that are therapeutic targets.
Deep sequencing has been used for the analysis of clinical
samples from individuals with HIV infection or other
viruses to identify the multiple related viral clones, often
referred to as ‘quasi-species’, that coexist in an infected
individual (1–4). This offers the opportunity to identify
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whose representation in a virus population can expand
after therapeutic selection in chronically infected individ-
uals. NGS can also provide sensitive detection of
cancer-speciﬁc mutations from primary clinical cancer
samples contaminated with normal stroma (5) and in a
similar context, these mutations can lead to cancer
therapy resistance. By pooling genomic DNA from
many individuals in a cohort and sequencing the pool,
one can identify rare variants from smaller size genomic
regions at a much lower per-sample cost than from large
population studies (6).
There are many experimental methods available for
highly sensitive detection of rare mutations and variants
from admixture samples containing multiple genotypes.
These include denaturing high-performance liquid chro-
matography (DHPLC) (7), high-resolution melting
analysis (HRMA) and mutation-speciﬁc PCR-based
genotyping assays (8). However, DHPLC and HRMA
require DNA sequencing as ﬁnal conﬁrmation of the
identity of a mutation and mutation-speciﬁc genotyping
assays (9), while highly sensitive and speciﬁc, require
a priori knowledge of the mutation. Compared to these
other methods, direct DNA sequencing offers signiﬁcant
advantages for both discovery and conﬁrmation of rare
mutations in samples that are complex genetic mixtures.
Presently, there are only a limited number of ways to
detect rare single nucleotide mutations using a NGS
platform (1,10–12). SNPseeker (11) uses quality ﬁltering
and large-deviation theory to call SNPs with a minor allele
frequency (MAF) as low as 0.5–1.2%. VarScan (10) uses
thresholds on coverage, quality and variant frequency
to call variants with a MAF as low at 1%. CRISP (13)
uses a probabilistic model to call rare variants present
in pools as large as 25 individuals representing a level
of 2% allele frequency. Hedskog et al. (1) report detection
of 0.07–0.09% variants in a viral population using
pyrosequencing technology. Some methods are designed
detect both SNPs and indels. The major challenge for
NGS rare variant and mutation detection is ﬁnding a
true signal with the relatively high error rates of NGS.
With the initial commercial release of these technologies,
these errors were generally quoted as ranging from 1% to
3% (14). We demonstrate that the error rates are signiﬁ-
cantly lower based on our results of sequencing a synthetic
DNA samples. Our overall objective was to develop a
robust and general method to detect rare (0.1%) single
nucleotide variants with current sequencing-by-synthesis
NGS technology by overcoming the general sequencing
error rate limitations. At this level, this represents
accurately detecting one mutation among 1000 wild-type
alleles.
Our method for the detection of rare single nucleotide
mutations at the 0.1% level relies on innovation in both
experimental design and statistical algorithm (Figure 1).
We use a multi-reference, indexed experimental design
to minimize experimental variance and characterize a
position-speciﬁc error distribution. We employ a
rigorous statistical model to estimate the position-speciﬁc
error rate distribution for reference sequences and thus the
probability of a true mutation at each position in the
sample. The statistical model provides a rigorous frame-
work for hypothesis testing and estimation that minimizes
false positives in variant calling. We demonstrate our
method by accurately calling known mutant positions in
a 0.1% mixture of two pure synthetic DNA constructs
sequenced via Illumina NGS. The reference and mutant
positions are known a priori and provide a gold standard
for testing our approach. We then apply our method to
identify mutations of the H1N1 inﬂuenza A (H1N1) neur-
aminidase gene (NA) obtained from nine infected individ-
uals during the 2009 pandemic. We identiﬁed a known
drug resistance mutation among these variants. Finally,
we show a statistical power analysis of our method in
order to characterize the sequencing parameters under
which our method can be generalized to other novel
applications.
Figure 1. Method ﬂowchart. The method for detecting rare variants
compares the baseline error rate from multiple reference replicates to
the sample error rate at each position. Sample and reference DNA are
independently prepared and tagged with indexed adapters. The refer-
ence and sample libraries are pooled and sequenced on the same lane.
The reads are aligned and preprocessed to ﬁlter out strand-speciﬁc
errors. The parameters of a Beta-Binomial model are ﬁt to the reference
sequence data to obtain a null hypothesis error rate distribution for
each position. Finally, the error rate of the sample sequencing data is
compared to the null distribution to call rare variants.
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Synthetic sequence construct
Two versions of a 300-bp completely synthetic sequence
were synthesized, which differ by a single base substitu-
tions in 14 positions spaced 20 bases apart (https://www
.dna20.com). The overall sequence length was 400bp
including the linkers (Supplementary Figure S1). The syn-
thetic inserts were cloned into a pUC based Kan
R con-
taining vector and the resulting 2971-base plasmid was
used as template for subsequent experiments.
Sample and sequencing preparation
In preparation for sequencing, PCR ampliﬁed DNA from
each template plasmid was prepared as follows: 50ul re-
actions were prepared consisting of 25ng template,
200uM dNTP, 1uM each of ampliﬁcation primers,
0.5ul (1U) of Phusion Hot Start enzyme (New England
Biolabs). We used the following ampliﬁcation conditions:
98 C 30s followed by 20 cycles of 98 C1 0 s ,6 0  C3 0 s ,
72 C 30s, followed by 72 C 7min, then hold at 4 C.
Twenty such reactions were combined for the wild-type
product and six for the mutant product. Wild-type and
mutant products were pooled separately and puriﬁed
(Qiagen QIAquick). Products were quantitated on a spec-
trophotometer (Nanodrop Instruments) and the concen-
tration was adjusted to 25ng/ul. The mutant DNA was
spiked into the wild-type to a ﬁnal concentration of 0.1%
of the total DNA. The sample was then split into three
technical replicates. The sequence of the two synthetic
templates and of the PCR primers used is provided in
the Supplementary Figure S1.
To prepare the sequencing library for each of the six
samples (0 and 0.1% dilutions in triplicate), each PCR
sample was concatenated using T4 DNA ligase (reaction
conditions: 500ng DNA, 1  Quick Ligation Buffer, 1ul
T4 DNA ligase in 50ul total volume for 10min at 25 C)
and fragmented using a Bioruptor sonicator (Diagenode)
with the following settings: 6 consecutive cycles with each
cycle consisting of 30s ‘on’, 30s ‘off’ for 15min on power
setting ‘high’). DNA was end-repaired: 30ul of frag-
mented DNA was combined in a 50ul ﬁnal reaction
volume containing 0.15U/ul T4 DNA polymerase,
0.5U/ul polynucleotide kinase, 0.05U/ul Klenow in 1 
T4 DNA ligase buffer w/ATP and incubated for 45min
at 25 C. End-repaired DNA was A-tailed using native Taq
polymerase (1  Taq buffer, 0.1mM dATP, 0.04U/ul Taq)
at 72 C for 15min. Reactions were puriﬁed using
Fermentas GeneJet
TM PCR puriﬁcation kit and eluted in
20ul TB buffer. Multiplex adapters were ligated for 1h at
25 C in 25ul reactions containing 1  T4DNA ligase
buffer, 0.15uM adapters, 1ul T4DNA ligase HC.
Adapter ligated material was puriﬁed using a 2% E-gel
SizeSelect, excising the 300–350bp fraction. The
gel-puriﬁed fraction was PCR enriched (reaction mix:
1  Phusion HF buffer, 250 uM dNTP, 1.2 uM enrichment
primers,   units Phusion Hot Start polymerase). We used
the following cycling conditions: 98 C for 30s, followed
by 15 cycles of 98 C for 10s, 72 C for 1min, then 72 C for
7min, then hold at 4 C. Enriched libraries were gel
puriﬁed on 2% E-gel SizeSelect. The 300-350bp fraction
was collected and quantitated using SybrGold ﬂuores-
cence assay (Invitrogen).
Sequencing library indexing
We developed a highly accurate 16-plex indexing strategy.
We synthesized a total of 32 versions of barcode adapters
that were used in a 16-plex indexing schema and the index
sequences are listed in Supplementary Table S1. The
modiﬁcation of the standard Illumina sequencing
adapter pair consists of all 16 dinucleotides combinations
added at the 50-end of one adapter molecule and all 16
combinations of the same dinucleotide ‘NN’ sequence plus
a ‘T’ inserted at the 30-end of the other standard Illumina
adapter sequence. For a given sample, we ligate a speciﬁc
matched pair of indexing adapters to double stranded
DNA such as an amplicon. Except for the modiﬁed
adapters, our design uses all the reagents and protocols
of the standard Illumina single-plex protocol while
obviating the need for the third read as commonly
employed for other multiplexing methods. To assign a
paired end read to an indexed bin we require that the
same tri-nucleotide (‘NNT’) be read as the ﬁrst three
bases of both mate pair sequence reads. As a test of the
indexing accuracy of this methods we generated 16 differ-
ent amplicons from different regions of the genome using
the methods as previously described (15). Using an an-
onymous normal diploid genomic DNA sample, these
amplicons were generated in simplex reactions.
Subsequently we used the standard Illumina protocol as
already noted to incorporate the indexing adapters to each
amplicon. The analysis regarding the indexing accuracy is
also located in Supplementary Table S1.
Sequencing, alignment and ﬁltering
Paired-end sequencing was performed on an Illumina
GAIIx sequencer (Illumina SCS 2.8) with real-time
image analysis and base calling (Illumina RTA 2.8).
Eland II (from Illumina pipeline version 1.6) was used
with the default parameters to perform sequence align-
ment to the 300-bp synthetic DNA construct. Aligned
data were ﬁltered to remove sequences with high error
rates (greater than two mismatches) and processed into
depth matrices. We ﬁnd the results quoted are not
altered by allowing three mismatches. The number of
mismatches allowed depends on the read length and the
expected mutation frequency. In addition, by comparing a
single sample that was run with replicates on two separate
lanes, we also determined intra-lane and inter-lane vari-
ability that was run on two different lanes (Supplementary
Figure S3).
After initial pre-processing and alignment of the
primary sequence reads, the error rates between
read-matched pairs on the same strand are highly
correlated (forward reads: r=0.94, 95% asymptotic con-
ﬁdence intervals (95% CI 0.94–0.95), reverse reads
r=0.94, 95% asymptotic conﬁdence intervals (95% CI
0.94–0.95)]. In contrast, the error rates between forward
and reverse strand reads are uncorrelated in general [ﬁrst
in pair: r= 0.08, 95% asymptotic conﬁdence intervals
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CI  0.23 to  0.09)] (Supplementary Figures S4–S6). For
a minority of positions, the error rate on one strand is
remarkably different than the same position as read on
the reverse strand. A signiﬁcant fraction of the
strand-speciﬁc errors are in 50-GT-30 sequences with an
error at the T position. Our observation is consistent
with Dohm et al. (16) who found that bases preceded by
G have a high error rate. We remove the higher error rate
direction reads that have a signiﬁcantly different error rate
between the forward and reverse directions
(P < 1   10 6,  >0:25 %) (Supplementary Figures
S7–S9).
H1N1 sample sequencing
The study was conducted under a clinical protocol
approved through the Stanford University School of
Medicine. We collected nasopharyngeal swab samples in
viral transport media. We conﬁrmed that these nasopha-
ryngeal samples contained the 2009 H1N1 inﬂuenza A
virus through a previously published method (17). We
isolated viral RNA using the Qiagen Viral RNA Mini
kits, and ampliﬁed using Superscript OneStep RT–PCR
reagents and two primers at positions 428 (AGG GCC
CTT GCT AAA TGA CA) and 1236 (AAC TCC CGC
TAT ATC CTG ACC ACT). Ampliﬁcation conditions
were 45 C for 30 C min, 94 C for 2min, 35 cycles of
(94 C for 15s, 54 C for 20 Cs ,7 2  C for 2min),
followed by 72 C for 7min. The reaction combines
10ul RNA and 40ul Master Mix containing per
reaction: 25ul 2  Reaction Buffer, 0.5ul each primer at
50pmol/ul, 1ul RT-Taq mix and 13ul water. The refer-
ence for this experiment is PCR ampliﬁed DNA for
plasmid GS2.3 using the same primers. Ampliﬁcation con-
ditions for the plasmid reference are 94 C for 2min,
35 cycles of (94 C for 15s, 54 C for 20s, 72 C for
2min], followed by 72 C for 7min. The reaction
combines 10ul of DNA at 1ng/ul and 40ul Master Mix
containing: 5ul 10  Reaction Buffer, 0.5ul each primer
(50pmol/ul), 1ul dNTP mix (10mM each), 1.5ul MgCl
(50mM) 0.2ul Platinum Taq (Invitrogen) and 31.3ul
water. All subsequent sequencing analyses were performed
as previously described.
Statistical model
Statistical analysis was conducted using Matlab
(Mathworks) and our analysis scripts are provided in the
Supplementary Data. We start with the sequencing error
rate that is simply deﬁned as the fraction non-reference
reads divided by the total reads. Subsequently we apply
the Beta-Binomial model (Supplementary Figure S10) that
is used to identify rare variants in reference sequence data.
Beginning with the observed data, rij is the non-reference
read count for experimental replicate i, at position j;n ij is
the total read count. The sequencing error rate for a given
position is f~ ¼ð r=nÞ. The random variable rij is distributed
as a Binomial with parameter  ij, which represents the true
error rate for position j in replicate i. The unobserved
random variable  ij is sampled once for each experimental
replicate and has a Beta distribution with parameters
 j ¼ M, j
  
. The parameter  j, j ¼ 1...J corresponds
to the prior error rate at position j. The parameter M is
the experimental precision of the error rate; equivalently a
pseudo-count for read depth at position j. We observe that
the error-rate variance is constant across positions (data
not shown) and is therefore represented unconditional on
position in the model.
The random variables and parameters are estimated by
the maximum-likelihood method using the expectation
maximization (EM) algorithm. The algorithm is initialized
with the plug-in moment estimates of  , and M. The EM
algorithm alternates optimizing the log-likelihood with
respect to   and with respect to   by the interior point
method until the change in the log-likelihood is <0.01%.
The expected value of y is estimated in closed-form, while
the parameters,   are estimated by a constrained
interior-point algorithm.
Experimental variation, caused by differences in sample
handling, sequencing library preparation, indexing and
the overall experimental protocol is captured in the experi-
mental precision parameter M, which is estimated through
the total variation in y across experimental replicates (see
‘Materials and Methods’ section for variable deﬁnitions).
The moment estimate for M in the Beta-Binomial model is
^ M ¼ð 1=J
PJ
j¼1 ^  j 1   ^  j
  
  s2Þ=ðs2   1=J
PJ
j¼1 ^  j 1   ^  j
  
1=N
PN
i¼1 1=nijÞ, where s2 ¼ NJ
PJ
j¼1
PN
i¼1 nij ^  ij   ^  j
   2
=
NJ   1 ðÞ
PJ
j¼1
PN
i¼1 nij and ^  ij ¼ rij=nij. The term s2
captures the variation in the error rates between replicates
in the summation
PJ
j¼1
PN
i¼1 nij ^  ij   ^  j
   2
and as s2 in-
creases, ^ M decreases. Since the number of positions is
generally ﬁxed for a sample of interest, more replicates
leads to an improvement in the accuracy with which ^ M
is estimated. Finally, for a given mutation the sample
fraction is ^ f ¼ f~  ^  0. When referring to the detection
level of mutations, we cite the sample fraction except
when otherwise stated.
Model parameter estimation
The EM algorithm is used to compute the maximum like-
lihood parameter estimates for f. It has been shown that
the expected complete log likelihood is a lower bound on
the log-likelihood of the data and the lower bound can be
maximized by coordinate ascent. We optimize Lc by
alternating constrained maximization. First we maximize
Lc numerically using an interior point algorithm with
respect to the parameters   ¼  ,M fg in the space
S ¼ 0,1 ½ 
J R+. Then we maximize Lc with respect to
 ij ﬁxing the parameters at ^  . The maximum likeli-
hood estimate has the closed form solution,
^  ij ¼ ^  i ^ M+rij   1= ^ M+nij   2.
Hypothesis testing
To test for rare variants in the model, the prior param-
eters, f, are estimated from reference data using the EM
algorithm. The prior parameters then contain the expected
error rates for the null hypothesis of no variant. Since
the Binomial distribution is well-approximated by a
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z-test is used to compare the observed Binomial error
rate (r/n) for a new sample to the reference null
distribution H0 ¼f rij=nij : Prðrij=nijj ^  ij0, ^ M0Þ >  g, with
mean Er =n ðÞ ¼  0 and variance  2
0 ¼ Var r=n ðÞ ¼
 0 1    0 ðÞ =n 1+n   1=M0+1 ðÞ . To improve the power to
resolve rare variants, it is optimal to make the
null-hypothesis variance,  2
0, as small as possible. If
y, then  2
0    0 1    0 ðÞ =n and the sequence depth be-
comes the limiting factor in the detection power.
Conversely, if n   M0, then  2
0    0 1    0 ðÞ =M0+1 and
the inter-replicate variation becomes the limiting factor.
Complete details of the model speciﬁcation and param-
eter estimation procedure are available in Supplementary
Data. Executable code for the parameter estimation and
hypothesis testing procedures are also available upon
request.
RESULTS
We show three results of our rare mutation identiﬁcation
method. First, we demonstrate our approach on a
controlled admixture of two synthetic DNA constructs
and compare our method to other available procedures
using this data. Second, we show a statistical power
analysis of our algorithm and characterize its limitations.
Third, we apply our method to nine clinical isolates of
H1N1 inﬂuenza A from the 2009 pandemic.
Synthetic DNA admixture sequencing analysis
Two versions of a 400-bp DNA sequence were
synthesized; the synthetic sequence makes up the internal
300bp with the remainder coming from polylinker se-
quences. The two versions of the sequences differ only in
14 known single nucleotide positions (mutations) and do
not map to any known genomes (Supplementary Figure
S1). We prepared sequencing libraries from these synthetic
sequences as described in the ‘Materials and Methods’
section (Supplementary Figure S2). A sample containing
pure reference sequence was independently indexed with
three unique barcodes. Similarly, a sample containing a
0.1% molar mixture of both sequences was indexed with
three different barcodes. The dominant sequence in the
mixture is the ‘reference’ sequence and the minor
mixture component is the ‘mutant’ sequence.
We sequenced the six indexed libraries (three pure ref-
erences and three 0.1% mutant admixture samples) on a
single lane of an Illumina GAIIx, and the resultant
paired-end data was aligned to the known synthetic refer-
ence to give a read depth at each position. For sequencing
error ﬁltering, all reads with more than two mismatches to
the reference were eliminated. Next, at positions where
reads from one strand (forward or reverse) had a high
error rate relative to reads from the other strand, the
strand-speciﬁc reads with high error were excluded. The
depth coverage for the synthetic DNA data prior to error
ﬁltration is 8:6   105 and 8:0   105 post-ﬁltration. The
analysis was restricted to the central 281 bases of the syn-
thetic DNA sequence; all 14 mutant positions were located
within this interval. We identiﬁed 6.4% (18/281) of the
positions as having a signiﬁcantly higher forward strand
error rate and 7.0% (20/281) of the positions as having a
signiﬁcantly higher reverse strand error rate. To assure
that alignment error did not affect the analysis, we
veriﬁed that the synthetic sequence was devoid of
internal repeats based on looking at 14 base strings incre-
mented through the entire synthetic reference.
Accurate assignment of indexed reads to the
appropriate sample
A potential source of error is the false assignment of
indexed reads from one sample to another. Other highly
efﬁcient methods for sample indexing are available, with
the majority using single reads for indexing. We developed
an accurate method for indexing using paired-end
sequencing and mate-pair reads. We incorporate a two
nucleotide indexing barcode followed by a third
common T at the 50-end. This barcode is the same for
the two adapters of a given sequencing library. To cor-
rectly assign a mate pair sequence to a given sample, we
require that the same barcode is present on both reads of a
given mate pair set. In other words, we assign a sequence
to a speciﬁc sample by imposing the presence of the
correct ‘NNT’ sequence at the 50-end of both Read 1
and of Read 2. To assign a read incorrectly to the
wrong sample would require identical sequencing errors
on the indexing tag on both pairs of the read.
Prior to our synthetic DNA resequencing studies for
rare variant detection, we determined the frequency of
false assignment errors for a given mate-pair indexing
barcode. To accomplish this assessment, we tagged 16 dif-
ferent amplicons independently, pooling them and
sequencing all of the 16 indexed libraries in a single lane
of an Illumina GAIIx. We generated 19,477,723 mate-pair
reads for a single lane. For all 16 barcodes, we observe
that 16,311,074 of the mate pair reads are associated with
the correct amplicon while just 11,255 are associated with
one of the other 15 amplicons. The remainder of the reads
represented adapter primer products that are commonly
seen. We deﬁne the indexing error rate as the number of
reads associated with an incorrect amplicon divided by the
total number of reads from the 16 amplicons. Overall, we
observe a 0.06% indexing error rate which was well below
our reported detection threshold (Supplementary Table
S1). Overall, using indexing barcodes that match on
both reads provided high accuracy assignments.
Sequencing error rate variation at a particular position
is less than variation across all reference positions
We deﬁne the position-speciﬁc sequencing error rate as the
fraction of the sum of the non-reference base read depths
over the total read depth at a particular position in a
sample (see ‘Materials and Methods’ section). In other
words, for each individual base position, we determine
the sequencing error rate. Figure 2 shows the
position-speciﬁc sequencing error rates for the three
indexed synthetic reference samples as a proﬁle across pos-
itions and as histogram density estimates. The variance of
the error rates is much greater for all combined positions
than for each position independently. Though the error
PAGE 5 OF 12 Nucleic AcidsResearch, 2012,Vol. 40,No. 1 e2rate of NGS technologies have been quoted to be 1–3%,
we observe that the average error rate across all positions
is 0.26% with an average standard deviation of 0.056%.
The error rate distribution is skewed towards higher error
rates with upper 95th percentile at 0.35% and the lower
5th percentile at 0.19%. The maximum error rate across
positions and experimental replicates is 0.66% and the
minimum is 0.13%. Since the rates are based on the trip-
licate reference which is a pure population, any errors are
a result of the library preparation or sequencing processes
effects. We minimized the PCR-induced errors in the prep-
aration of the reference by using Phusion, a high ﬁdelity
polymerase, a large amount of template (25ng) and a
small number of ampliﬁcation cycles in the preparation
of the reference DNA.
While the sequencing error rate across the entire refer-
ence sequence is highly variable, sequencing error rate at
each speciﬁc position is signiﬁcantly less variable. The
sequencing error rate density estimates in Figure 2 show
that the variance in sequencing error rates across positions
is much greater than the variance within a speciﬁc position
(ﬁve sample positions displayed). For the reference
sequence, the total variance across positions and replicates
is 3:20   10 7. The variance across positions is 3:13   10 7
and the average variance within a base position is
7:52   10 9. Thus, the average standard deviation of the
error within a base position is 0.0086% compared to
0.056% across positions—more than 6-fold smaller.
Statistical model detects mutated positions at a sample
fraction of 0.1% level
We developed a binomial error model that categorizes a
sequence read as ‘reference’ or ‘non-reference’—an excess
of ‘non-reference’ reads indicates the presence of a variant
at the position. By using a Beta distribution prior on the
binomial parameter representing the sequencing error
rate, we more accurately capture the variance in the
position-speciﬁc distribution across replicates that in
turn decreases the false positive rate of our algorithm.
Derived from our Beta-Binomial model analysis, the
sample fraction value indicates the fractional representa-
tion of rare mutations from the sample of interest.
The Beta-Binomial model parameters (f) were ﬁt to
reference-only sequencing data. The reference error rate
as estimated in the model was compared to the actual
sample error rate (error read depth/total read depth)
derived from sequencing (Figure 3). As expected, the
reference-based estimates of the position-speciﬁc error
rates (y) were reproducible across replicates and no sig-
niﬁcant differences between the reference error rates,m,
and the sample (Binomial) error rates were detected
(Figure 3). In contrast, the sample error rate estimates
for the 0.1% admixture population shows some positions
with signiﬁcant differences (P<1 10
 6) between the ref-
erence error rate and the sample error rate indicating the
presence of a variant (Figure 3). Setting the threshold
P-value at   ¼ 1   10 6 is equivalent to a Bonferroni cor-
rected level of   ¼ 1   10 3 for a 1-kb target region and
thus has a low false positive rate after controlling for
multiple hypothesis testing.
The algorithm correctly identiﬁes all 14 mutation pos-
itions out of 281 total sequenced bases in each of three
replicates. The average speciﬁcity across three replicates to
detect a variant admixture at a 0.1% level with 100%
sensitivity is 99% (Table 1). The Beta-Binomial model
misidentiﬁed 5, 4 and 1 positions out of 267 as variant
for the three replicates. There were no type II errors in
Figure 2. Position-speciﬁc error rate distribution. The average sequence error rate variance across positions is signiﬁcantly greater than the average
variability at each position. The across-position distribution is shown on the right side in dark blue and a sample of ﬁve within-position density
estimates is shown below it. The empirical within-position and across-position distribution estimates show that a small number of outlying positions
contribute to the excessive variance in the across-position distribution.
e2 Nucleic AcidsResearch, 2012,Vol. 40,No. 1 PAGE 6 OF 12this data set. The precision and accuracy of the approach
is high.
Due to the small number of variant positions (5% of the
total sequence) the false discovery rates for the three rep-
licates are 0.26, 0.22 and 0.067. The false discovery rate is
high due to the low number of true positives compared to
true negatives in the sequence. Taking a consensus
approach across replicates signiﬁcant improves the speci-
ﬁcity to 100% and reduces the false discovery rate. Given
the issue of the true positives relative to the true negatives
being highly skewed (18), we report a balanced measure
for the classiﬁcation accuracy using the Matthews
Correlation coefﬁcient (MCC) as was done for the
MAQCII analysis (19). Our method has an average
MCC score of 0.896 where a value 1 indicates perfect clas-
siﬁcation accuracy. These results are based on testing for
statistical signiﬁcance alone. Combining our statistical test
with a effect size test such that only those called mutations
with an estimated mutant sample fraction is  0.1%
reduces the number of false positives to zero. While the
sensitivity is reduced, in some applications, such as the
analysis of long sequences with infrequent mutations,
a much more speciﬁc test is more appropriate.
Comparison of our approach to other methods
We compared our Beta-Binomial model to an approach
that uses only the overall error rate distribution across all
positions and to the method of Hedskog et al. (1), which
uses pyrosequencing data to develop a position-speciﬁc
error rate comparison in order to identify mutations at a
0.05% sample fraction level. We applied all methods to
the identical synthetic DNA data set. Hedskog et al. (1) do
not employ a statistical model to estimate the error rate.
Our approach has a lower error rate than either of these
alternative approaches (Table 2). Using the same data set,
commonly used variant callers including the Genome
Analysis Toolkit (GATK) (20) and SAMtools (21) do
not detect any true variants on this data set.
For pyrosequencing data (e.g. 454 sequencing), the
Hedskog method has power to detect mutations at
0.05%, but we ﬁnd it to be less sensitive for our data.
Figure 3. Variant positions in the 0.1% mixture sample of synthetic DNA are identiﬁed by the statistical model. The x-axis is the reference error rate
as estimated by   in the model and the y-axis is the sample error rate (error read depth/total read depth). True negatives (black), true positives (blue)
and false positives (red) for three replicates are identiﬁed in both samples. For each of the three replicates, the model ﬁnds 14 of 14 true positives; 5,4
and 1 additional calls (false positives), respectively, are made. Requiring a consensus call of all three replicates eliminates these false positives.
Table 2. Comparison of high sensitivity methods of minor allele
detection
Sensitivity (%) Speciﬁcity (%)
Sample 1
Hedskog et al. (1) 0/14 (0) 267/267 (100)
Across-position method 0/14 (0) 267/267 (100)
Position-speciﬁc method 14/14 (100) 263/267 (98.13)
Sample 2
Hedskog et al. (1) 0/14 (0) 267/267 (100)
Across-position method 0/14 (0) 267/267 (100)
Position-speciﬁc method 14/14 (100) 263/267 (98.50)
Sample 3
Hedskog et al. (1) 0/14 (0) 267/267 (100)
Across-position method 0/14 (0) 267/267 (100)
Position-speciﬁc method 14/14 (100) 266/267 (99.63)
Table 1. Ultrasensitive detection of 0.1% minor mutant alleles
Sample
0.1% admixture replicate
1 2 3 Average
Sensitivity 1.000 1.000 1.000 1.000
Speciﬁcity 0.981 0.985 0.996 0.987
False positive rate 0.019 0.015 0.004 0.013
False negative rate 0.000 0.000 0.000 0.000
Positive predictive value 0.737 0.778 0.933 0.816
Negative predictive value 1.000 1.000 1.000 1.000
Accuracy 0.982 0.986 0.996 0.988
False discovery rate 0.263 0.222 0.067 0.184
Matthews correlation coefﬁcient 0.850 0.875 0.964 0.896
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mates of the error rate at each position that lowers the
statistical power. Also, it employs a data-cleaning method
for pyrosequencing to reduce the average error rate to
0.05% and report a detection limit of 0.07%. When the
Hedskog method is applied to sequence data from an
Illumina Genome Analyzer, the detection limit is less sen-
sitive. In the case of the across-positions error model
approach, the average sequencing error rate is  0.25%
and the detection limit is necessarily greater for
error-prone positions. We are not fundamentally limited
by the average error rate across positions; our sensitivity
depends instead on the variance of the error rate across
replicate sequencing of the references at each position. We
improve the reproducibility by controlling inﬂuential ex-
perimental parameters and sequencing the reference and
samples in the same lane. Further improvements in experi-
mental reproducibility are expected to improve the detec-
tion limit.
Statistical algorithm analysis
In order to identify mutations, we look for positions with
a higher error rate than would be expected if the sequence
originated from a sample that is purely reference DNA.
We use the reference sequence data to estimate the par-
ameters in our model. We then compare the observed
error rate in a sample sequence to the estimated reference
distribution in a classical hypothesis-testing framework.
A characterization of the model provides insights into ap-
propriate experimental design conditions.
Experimental variation is caused by differences in
sample handling, sequencing library preparation,
indexing, which we capture in the beta distribution experi-
mental precision parameter. Our model indicates clear
roles for experimental precision and overall read depth
in improving rare variant detection levels. The iterated
moment estimate for M in our Beta-Binomial model
captures the variation between positions and within each
position across replicates. Increasing the number of repli-
cates improves the accuracy by which M is estimated (see
‘Materials and Methods’ section).
The relationship between experimental precision, read
depth and variant detection limit is shown in power curve
analysis in Figure 4. The experimental precision parameter
we deﬁne as M0. The read depth controls the sampling
variation and the accuracy with which we observe the
true error rate. If the read depth is too low, the uncertainty
in the true sequencing error rate will be too high to call a
less prevalent, rare variant as a statistically signiﬁcant dif-
ference from the reference position. For example, if the
read depth at a position is only 60, we will not detect a
variant present in 1 out of 1000 reads. However, if the read
depth is 10000, the sampling error of the binomial distri-
bution may be sufﬁciently small to detect a variant at
0.1% sample fraction.
Holding the read depth ﬁxed at 10000 and the level of
the test at   ¼ 0:01, the power improves signiﬁcantly as
M0 increases from 100 to 10000 (Figure 4a). This is
directly related to improvements in experimental design
such as the reproducibility of replicates. As M0 increases
to 1   105 and 1   106 we see only a marginal beneﬁt in
statistical power indicating that the read depth has become
limiting. Likewise with M0 ﬁxed at 10000 and   ¼ 0:01,
we see that further increases of sequencing depth beyond
10000 provide no major beneﬁt for detection (Figure 4b).
The detection sensitivity increases as both the experimen-
tal precision and read depth increase (Figure 4c). Holding
the reference error rate ﬁxed at 0.25%, the detectable
variant frequency is below 0.5% at n ¼ 1   106,
M0 ¼ 1   106 and asymptotically approaches 0.25%.
The expected ROC curve shows that for M0 of 10000a
read depth of 10000 yields good power (>90%) at a low
false positive rate to discriminate a reference error rate of
0.25% from a variant fraction of 0.5%. Higher read
depths 105   106 yield nearly perfect classiﬁcation under
theoretical conditions (Figure 4d). For the ROC analysis,
the area under the curve (AUC) for the read depth from
102   106 is 0.61, 0.80, 0.97, 0.996 and 0.997.
Rare mutations in the NA gene in clinical samples of
H1N1 inﬂuenza A
We sequenced nine independent clinical samples of H1N1
inﬂuenza NA gene using the indexing method described in
two replicate sequencing lanes. Given that these were
clinical samples, we use a replicate lane to improve our
assessment of variance. One sample (BN1) was replicated
within each lane and one sample (B23) was diluted 5-fold
and 25-fold with the reference NA gene within each lane
to assess reproducibility and sensitivity. The replicated
reference was sequenced from a single plasmid clone con-
taining the NA gene isolated from an individual infected
with H1N1. All sequence data are reported as relative
positions to the H1N1 strain A/California/07/2009
(Genbank reference GQ377078). We used the high
coverage sequence data from position 468–1183 in the
H1N1 reference. The reference NA sequence contains
three nucleotide mutations G1044A, A1052T and
T1059C compared to the GQ377078 sequence, which
introduces one amino acid mutation, Y351F.
The average coverage depth is 2:42   105 for the
samples in lane 1 and 2:48   105 in lane 2 before prepro-
cessing and 2:08   105 for lane 1 and 2:21   105 for lane 2
after pre-processing. Our pre-processing ﬁlter identiﬁed
100 positions with high relative forward strand error
rates and 106 positions with high reverse strand error
rates in lane 1. The corresponding counts for lane 2 are
80 and 84. Overall, the reference sequence data in lane 1
showed an overall higher average sequencing error rate of
0.45%, compared with 0.22% for lane 2. However, the
critical parameter for our approach, the average
within-position standard deviation, was very similar at
0.017% in lane 1 and 0.013% in lane 2.
Figure 5a shows the full spectrum of detected NA mu-
tations for the nine H1N1 clinical samples derived from
the consensus. On average for the variants at 0.1% sample
fraction or higher, we identiﬁed an average of 40 muta-
tions per sample in lane 1 and 45 mutations per sample in
lane 2. Taking a consensus of both sequencing lanes gives
an average of 32 mutations per sample at or greater than
the 0.1% level (Supplementary Table S2). For the
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per sample (Supplementary Table S3). For three replicate
reference controls, there was only a single case where an
erroneous call was made when examining sequence data
from both lanes. The lack of called mutations from the
reference is a general indicator of overall quality of our
mutation detection.
Figure 5b shows that even though the sequencing error
rates varied from lane to lane, our detection method is
unaffected by such systematic differences. Please note
that the ‘raw’ sequencing error rates are derived directly
from the raw sequence data prior to our statistical model
analysis. For example, a detailed view of a 10-bp segment
of sample BN3 shows the sequencing error rates for lanes
1 and 2. The average of the sequencing error rate for lane
1 is higher than lane 2, but the critical error differential
between the reference and sample error rate, is
reproducible between the two lanes. Sequence logos for
the non-reference bases at each position show that the
positions called mutant due to excessive error rate are
indeed enriched for a particular base sequence.
To assess experimental reproducibility of our method,
we compared the identiﬁed mutations for BN1 across rep-
licates within a sequencing lane and between lanes
(Supplementary Figure S3). BN1 was indexed on two dif-
ferent lanes and we compared the results. The concord-
ance between replicates is high for sample fractions
>0.1% and diverges for fractions less than that level.
At position 826 in the NA gene, we identiﬁed the
H275Y mutation responsible for oseltamivir resistance in
one clinical sample (BN9). Oseltamivir speciﬁcally inhibits
NA activity and appearance of this resistance mutation
was a source of signiﬁcant concern given its public
health ramiﬁcations. The mutation is apparent even
Figure 4. Detection power depends on both read depth and experimental precision. We show here that the statistical power of the model, the
likelihood of detecting a true positive at a given effect size (level of prevalence), increases with read depth and sample preparation precision, up to
asymptotic limits. (a) Read depth (n) is held constant at an example level of 10000 and it can be seen that power increases with experimental
precision (M0) up to a limit of approximately 0.4 for an effect size of 0.1%. (b) When the experimental precision (M0) is held constant at 10000,
power increases with read depth (n) up to a limit of approximately 0.4 for an effect size of 0.1%. (c) For a ﬁxed false positive and false negative rate,
the detectable effect size decreases with both increasing sample preparation precision (M0) and read depth (n). A greater gain is achieved by
improving sample preparation precision than by increasing read depth if the experimental variation is large. (d) The ROC curve for a ﬁxed effect
size and sample preparation precision improves rapidly as the read depth increases. Read depth limits the sensitivity at all false positive rates when
low, but when read depth is high the ROC curve approaches an asymptotic curve controlled by the experimental variation.
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This is shown in Figure 5c where we display a breakdown
of the individual sequencing error rate for the
non-reference bases at codon position 1 for all of the
H1N1 clinical samples. The dotted line indicates the
expected error using the total sequencing error rate.
After our Beta-Binomial model analysis, we determined
that the H275Y mutation in BN9 had a sample fraction
of 0.18% that matches well with the difference between
expected per-base error rate and the observed fraction of
reads with a T base at the position in sample BN9.
To assess the sensitivity of our method we diluted the
B23 sample 5-fold and 25-fold with reference NA DNA.
Afterwards, we sequenced the admixtures. We determined
the dilution level at which point we could determine mu-
tations from the undiluted B23 sample. At two
non-synonymous positions 604 and 742 in the undiluted
sample B23, our algorithm calls mutations at sample frac-
tions of 0.66 and 99.45%, respectively (Supplementary
Table S3). Both positions were called in both replicate
experiments in the 5-fold diluted sample and only the
742 position was called in the 25-fold diluted sample. In
this dilution series, we did not detect the other B23 muta-
tions that were diluted to <0.1% sample fraction. This is
consistent with our rare mutation sensitivity threshold as
we demonstrated with the synthetic sequence. One B23
non-synonymous mutation was called at the 25-fold
dilution that was not identiﬁed in the undiluted sample.
This clearly is a false positive, but with this sole exception,
the dilution experiment veriﬁed the robustness of our
ultrasensitive mutation detection.
DISCUSSION
We have shown that by sequencing a known reference
sequence in multiplexed replicates with samples of
interest and integrating a Beta-Binomial statistical model
we are able to sensitively detect rare variants and muta-
tions at low (0.1%) sample fraction levels. This represents
one mutant allele being detected from among 1000
wild-type alleles in a single sample. We experimentally
Figure 5. Sequencing results of clinical samples of H1N1 inﬂuenza A. (a) A red dot indicates a position called as a mutant (P < 1   10 6) and has a
sample fraction >0.1% and green dots indicate an estimated sample fraction >1%. (b) A detail display of 10 positions in sample BN3 shows the
difference between the reference and sample sequencing error rates for called mutations in two replicate lanes. The non-reference base composition
for both lanes (in sequence logo format) shows that the three mutations are T to C pyrimidine transitions. (c) We identiﬁed the H275Y mutation
responsible for oseltamivir resistance in one clinical sample (BN9). Across all of the H1N1 clinical samples, we display a breakdown of the individual
sequencing error rate for the non-reference bases at codon position 1. The mutation in sample BN9 is readily apparent. The dotted line indicates the
expected base error rate from a uniform distribution across bases using the total sequencing error rate.
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a synthetic DNA sequence. We used our model to provide
a detailed analysis of the tradeoff between experimental
precision/reproducibility and sequencing depth to achieve
ultrasensitive variant detection. Our approach is best
suited toward studies that require analysis of small
regions such as viral and human genes that are drug
targets.
There is an observable lane–lane error rate bias on the
NGS platform (data not shown). We controlled this vari-
ation by sequencing the reference and samples in multiplex
on the same lane, but this control limits the number of
samples multiplexed, sequence length and detection limit.
Further improvements to the Beta-Binomial model are
required to adjust for the bias by normalization rather
than by control.
Our results have implications for experimental design
for multiple applications. While our initial application
was to identify mutations in the H1N1 inﬂuenza NA
gene, including those that lead to drug resistance, our
approach is also broadly applicable to identifying rare
mutations for speciﬁc genes in cancer samples,
characterizing viral quasispecies samples such as HIV
and analyzing other clinical samples that are genetically
heterogeneous. A ﬁxed total amount of sequence (T) can
be decomposed into a product of read depth (n), number
of multiplexed samples (q) and sequence length (l). This
can be stated as T ¼ n   l   q. The tradeoff between
sample throughput and detection limit can be optimized
for a particular experiment. For example, at the current
sequencing capacity of a single lane of an Illumina HiSeq
instrument, one could detect 0.1% variants in a 1kb target
sequenced at an average depth of 100000 for 10 samples.
Our model is optimized for detection of mutations in
viral genomes, and can be extended to other applications.
For tumor mutation detection, the reference genome
is haploid and point mutation may represent a loss-
of-heterozygosity event. Such an application would be ad-
dressed by extending our model to diploid genomes using
a Dirichlet-Multinomial model form. Furthermore, in-
corporation of sequence quality metrics would improve
detection, though it is unclear at this stage how much
gain is available with such side-information.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online:
Supplementary Tables 1–3, Supplementary Figures 1–10,
Supplementary Methods and Supplementary Data.
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